We caught up with Jana Thomas of Radboud University Medical Centre to find out more about the bidirectional relationship between poor sleep and Alzheimer’s disease.
Examination of the neural basis of psychotic-like experiences in adolescence during processing of em
We caught up with Dr Evan Papanastasiou from King's College London to find out why he chose CANTAB to examine the neural basis of psychotic-like experiences in adolescence during processing of emotional faces.
Despite chemotherapy-associated cognitive impairment (CACI, aka chemobrain) affecting 75% of all cancer survivors, little is understood about the mechanisms underlying the disorder. In efforts to address this research gap, Prof Alexandre Chan from the University of California, Irvine used CANTAB to conduct an evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment. Read on to find out the results.
We caught up with Lydia Devenney from Letterkenny Institute of Technology to find out why she chose CANTAB to assist her research into investigating attention, memory functioning, and mood in a natural setting with real‐life alcohol consumption levels.
What is the impact of stress and environment on executive function and motivation for primary school
We caught up with Toby Bartle, Registered Psychologist and PhD Candidate at James Cook University, to find out why he chose CANTAB when looking at the impact of stress and environment on executive function and motivation for primary school children.
We caught up with University of Ulster researcher, Kyle Wallace, to find out why he chose CANTAB to investigate the links between cognitive function, hydration status and martial arts.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes.
Mental health researcher at the University of Sydney: Brain and Mind Centre, Ashleigh Tickell, recently submitted her PhD on the feasibility of cognitive screening as standard clinical care in a young adult mental health unit. We caught up with Ashleigh to find out the outcomes of using CANTAB for her project.
We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks.
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017.
We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Winner of the 2016 Global Prize for the CANTAB Research Grant, Toni McCrossin, Clinical Officer for the New South Wales Brain Tissue Resource Centre (NSWBTRC) explains how access to CANTAB cognitive assessments are supporting their project.
Dr Jenny Barnett, Chief Scientific Officer for Cambridge Cognition reviews how the rise of touchscreen technology has enabled the expansion of cognitive assessment.
The early identification of individuals at risk of Alzheimer's Disease (AD) is of primary importance for the development of new effective interventions to stop the progression of the disease before the onset of severe neurodegeneration and clinical manifestations.
Cognition is essential for everyday functioning - here's why.
When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?